Physician profile
Sanjay Verma
NPI 1770536138
$1,901.64
in general payments reported to CMS, 2019-2025
14 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,235 · 2020: $51.29 · 2021: $25.43 · 2022: $35.45 · 2023: $100 · 2024: $213 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.49 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $946.29 | 2019 | |
| Janssen Biotech, INC. | $235.68 | 2021-2025 | Tremfya |
| Tempus Ai, INC | $120.64 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.13 | 2019-2022 | |
| Allergan, INC. | $110.40 | 2019 | |
| Abbvie INC. | $82.57 | 2020-2024 | Viberzi, Linzess |
| Lilly USA, LLC | $60.68 | 2023-2024 | Omvoh |
| Pfizer INC. | $43.40 | 2019-2025 | |
| Celgene Corporation | $40.75 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $35.05 | 2019 | |
| Qol Medical, LLC | $30.50 | 2019 | |
| Genzyme Corporation | $29.71 | 2024 | |
| Ironwood Pharmaceuticals, INC | $27.60 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $18.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.